Our most advanced small-molecule drug candidate, TQS-168, is currently in Phase 1 clinical development for the treatment of neurodegenerative disease, ALS. As a fatal orphan disease, ALS represents a prominent unmet need in which we aim to validate our approach and unlock the potential of our platform.
In multiple in vivo pharmacology neurodegeneration models, TQS-168 has demonstrated excellent blood brain barrier penetration, the ability to reverse myeloid cell dysfunction through PGC1α activation, and the capacity to ameliorate disease.
It has been shown to extend survival in a mouse ALS model. TQS-168 also has compelling biomarker evidence in animal models and ALS patient blood.
It will enter Phase 2 clinical studies in ALS in 2023, setting the stage for potential future indications in neurodegeneration, mitochondrial diseases, and other diseases of high unmet need.
Our second candidate, TQS-621, has started IND-enabling work and is expected to enter clinical development in the near future. This promising follow-on compound is slated to be studied in a number of non-orphan neurodegenerative and systemic diseases, including Parkinson’s disease, Alzheimer’s disease and more.
Additionally, we have screened more than 200 molecules, representing potential next-generation PGC1α regulators and immunometabolic or inflammatory targets in adjacent myeloid cell pathways.